Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00694551
Recruitment Status : Completed
First Posted : June 10, 2008
Results First Posted : February 19, 2014
Last Update Posted : October 4, 2019
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

Tracking Information
First Submitted Date  ICMJE June 4, 2008
First Posted Date  ICMJE June 10, 2008
Results First Submitted Date  ICMJE January 6, 2014
Results First Posted Date  ICMJE February 19, 2014
Last Update Posted Date October 4, 2019
Actual Study Start Date  ICMJE December 2, 2008
Actual Primary Completion Date February 28, 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 6, 2014)
Occurrence of Related Adverse Events - Grade 3 or Higher [ Time Frame: Up to 48 months ]
Number of participants with related Grade 3 or higher adverse events. Establish the safety and toxicity of varying doses of polypeptide vaccines PSMA and TARP administered with a fixed dose of Poly IC-LC as an adjuvant.
Original Primary Outcome Measures  ICMJE
 (submitted: June 9, 2008)
Establish the safety and toxicity of varying doses of polypeptide vaccines PSMA and TARP administered with a fixed dose of Poly IC-LC as an adjuvant. [ Time Frame: Approximately 24 months ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 5, 2015)
  • Number of Participants With Prostatic Specific Antigen (PSA) Doubling [ Time Frame: Up to 48 months ]
    Number of Participants Who Had a Doubling of the PSA or Proceeded to Another Therapy. Assess the impact of the vaccine on the pattern of PSA change in patients with castrate testosterone level and in patients with non-suppressed testosterone level not on hormone therapy.
  • Number of Participants Who Did Not Have PSA Doubling [ Time Frame: Up to 48 months ]
    Number of participants who did not have a PSA doubling before their last study visit, median 458 days from baseline PSA (55-613).
Original Secondary Outcome Measures  ICMJE
 (submitted: June 9, 2008)
Assess the impact of the vaccine on the pattern of PSA change in patients with castrate testosterone level and in patients with non-suppressed testosterone level not on hormone therapy. [ Time Frame: Approximately 24 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Official Title  ICMJE Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Brief Summary

Pilot Immunotherapy Study of Combination Prostate Specific Membrane Antigen (PSMA) and T-cell receptor γ alternate reading frame protein (TARP) Peptide With Poly IC-LC Adjuvant in Human Leukocyte Antigens (HLA)-A2 (+) Patients With Elevated prostatic specific antigen (PSA) After Initial Definitive Treatment

The purpose of the study is to see if the PSMA/TARP proteins in the vaccine, along with the Hiltonol, can arouse and train the immune system to kill the prostate cancer cells. Prostate cancer is the most common cancer and is the second leading cause of cancer deaths in U.S. males. It is curable when it is confined to the prostate (kept from spreading) using surgery or radiation treatments. In some patients the cancer can come back after these treatments. Treatment options for prostate cancer that comes back include procedures or medications which may have significant risks and side effects. Another plan is being looked at that uses the body's immune system to attack prostate cancer cells. A vaccine has been developed that has proteins found in prostate cancer cells. One of the proteins is called PSMA and the other is called TARP. In addition to these proteins, another substance called Poly IC-LC (Hiltonol) will be added to the vaccine to boost its ability to start the immune system.

Detailed Description

Detailed Objectives:

  1. Estimate the frequency of immunological efficacy of the vaccine by comparison of the in vitro enzyme-linked immunosorbent spot (ELISpot) test results, for each antigen (PSMA, TARP) from peripheral blood specimens collected during the periods of time defined as "before", "during" and "after" vaccination.
  2. Study the safety and toxicity of varying doses of polypeptide vaccines: PSMA27-35-PSMA687-701 (VLAGGFFLLYRHVIYAPSSHNKYA) and TARP13-35 (LQLLKQSSRRLEHTFMFLRNFSL) administered with a fixed dose of Poly IC-LC (2 mg total/treatment) as adjuvant.
  3. Describe the impact of the vaccine on the pattern of PSA change in 2 subsets of patients: with castrate testosterone; with non-suppressed testosterone level/not on hormone therapy.
  4. Identify if there is a basis for selection of a dose of the PSMA and the TARP polypeptide vaccines for future phase II development of this vaccination strategy, considering the dose range tested.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prostate Cancer
Intervention  ICMJE
  • Biological: Peptide Vaccine
    Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
    Other Names:
    • Hiltonol
    • poly IC-LC
    • PSMA peptide vaccine
    • TARP peptide vaccine
  • Drug: Poly IC-LC
    Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
    Other Names:
    • Hiltonol
    • NSC-301463
Study Arms  ICMJE
  • Experimental: A. Level 100 mcg Peptide Vaccine
    Peptide vaccine dose level 100 mcg + Poly IC-LC
    Interventions:
    • Biological: Peptide Vaccine
    • Drug: Poly IC-LC
  • Experimental: B. Level 300 mcg Peptide Vaccine
    Peptide vaccine dose level 300 mcg + Poly IC-LC
    Interventions:
    • Biological: Peptide Vaccine
    • Drug: Poly IC-LC
  • Experimental: C. Level 1 mg Peptide Vaccine
    Peptide vaccine dose level 1 mg + Poly IC-LC
    Interventions:
    • Biological: Peptide Vaccine
    • Drug: Poly IC-LC
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 8, 2013)
29
Original Estimated Enrollment  ICMJE
 (submitted: June 9, 2008)
75
Actual Study Completion Date  ICMJE December 6, 2018
Actual Primary Completion Date February 28, 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • History of histologically confirmed prostate cancer.
  • Competence to understand the patient information and provide written informed consent, and willingness and ability to return to H. Lee Moffitt Cancer Center for planned treatments and follow-up.
  • Absence of evidence of metastatic disease by current physical exam or by current imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI] pelvis, and bone scan within 60 days of first treatment).
  • Patients not on hormone therapy (stratum "N") must meet all of these:

    1. At least 1 year after prostatectomy, definitive prostate radiation, or other definitive-intent local therapy.
    2. No testosterone suppression therapy for at least 6 months.
    3. PSA at least 1 ng/ml, on 2 measurements, at least 2 weeks apart.
    4. Testosterone level >100 ng/ml, at start ("noncastrate").
  • Patients on hormone therapy (stratum "Y") must meet all of these:

    1. On treatment with gonadotropin-releasing hormone (GnRH) agonist (or orchiectomy) at least 6 months.
    2. testosterone level <50 ng/ml, at start.
    3. PSA at least 1 ng/ml, on 2 measurements, at least 2 weeks apart.
  • Laboratory values obtained 0-14 days prior to start of therapy:

    1. White blood count (WBC) over 3,500/micro L.
    2. Platelet count over 100,000 micro L.
    3. Hemoglobin over 10.0 g/dL.
    4. Serum creatinine up to 2.0 mg/dL.
    5. Alkaline phosphatase up to 2.5 x upper limit of normal (ULN).
    6. Aspartic transaminase (AST) up to 2.5 x ULN.
  • Life expectancy at least 6 months.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.

Exclusion Criteria:

  • Known standard therapy for the patient's disease that is potentially curative.
  • A known immunodeficiency including HIV. Appropriate trials for individuals with HIV may be considered at a later date.
  • History of other malignancy besides prostate cancer in the last 5 years, except non-melanoma skin cancer treated with local resection only. (The effect of study treatment on other, potentially dormant malignant diseases is not known).
  • Use of oral or inhaled or parenteral corticosteroids or of other immunomodulatory drugs within the 60 days of start. [Use of steroids after start will be considered by the principal investigator (PI) on a case-by-case basis.]
  • Use of estrogens (including herbal phytoestrogens) or ketoconazole within 30 days of start, or during the study.
  • Failure to fully recover to grade 1 or better from effects of prior chemotherapy regardless of interval since last treatment.
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational agent in last 30 days (one month washout to start of treatment; patients could register but not start until the washout).
  • Known hypersensitivity to one or more components of the study medication.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Puerto Rico,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00694551
Other Study ID Numbers  ICMJE MCC-15262
106346 ( Other Identifier: USF IRB )
20-14555-05-01 ( Other Grant/Funding Number: SPORE in prostate cancer - Pro )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party H. Lee Moffitt Cancer Center and Research Institute
Study Sponsor  ICMJE H. Lee Moffitt Cancer Center and Research Institute
Collaborators  ICMJE National Institutes of Health (NIH)
Investigators  ICMJE
Principal Investigator: Mayer Fishman, M.D., Ph.D. H. Lee Moffitt Cancer Center and Research Institute
PRS Account H. Lee Moffitt Cancer Center and Research Institute
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP